Back to search

Peptide record

TPDB26442

Antibacterial Anticancer Antiviral Toxicity modified_plain modified
28 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB26442
Antibacterial Anticancer Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia DRAVP 2.0
modified_plain
Yes
A 28-aa modified multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia and DRAVP 2.0, with an available 3D structural model.
Modified, details unspecified
Sequence
WEQKIEELLKKAEEQQKKNEEELKKLEX
Physicochemical Analysis
C150H249N39O50
RDCGHMFPSTYV
E
3398.86
4.80
7
9
7
-2
22.70
-1.864
73.21
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
5500
161.82
4
Residue Composition
number
1
A
0
R
1
N
0
D
0
C
9
E
3
Q
0
G
0
H
1
I
4
L
7
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 0 C: 0 E: 9 Q: 3 G: 0 H: 0 I: 1 L: 4 K: 7 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
28
C150H249N39O50
3398.86
4.80
-2
22.70
-1.864
Evidence Records 7 records
Evidence 1 Activity

Activity

50% Cytotoxicity
Toxicity
88.86±6.68 µM
Cytotoxic
50% Cytotoxicity | 88.86±6.68 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Structural and Functional Characterization of Membrane Fusion Inhibitors With Extremely Potent Activity Against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | J Virol | 2018
Evidence 2 Activity

Activity

50% Cytotoxicity
Toxicity
114.8±12.68 µM
Cytotoxic
50% Cytotoxicity | 114.8±12.68 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Structural and Functional Characterization of Membrane Fusion Inhibitors With Extremely Potent Activity Against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | J Virol | 2018
Evidence 3 Activity

Activity

50% Cytotoxicity
Toxicity
80.45 µM
Cytotoxic
50% Cytotoxicity | 80.45 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 4 Activity

Activity

50% Cytotoxicity
Toxicity
78.52 µM
Cytotoxic
50% Cytotoxicity | 78.52 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 5 Activity

Activity

50% Cytotoxicity
Toxicity
72.23 µM
Cytotoxic
50% Cytotoxicity | 72.23 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 6 Activity

Activity

50% Cytotoxicity
Toxicity
37.37 µM
Cytotoxic
50% Cytotoxicity | 37.37 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques. | PLoS Pathog | 2019
Evidence 7 Activity

Activity

Toxicity
Cytotoxic
Cytotoxicity: [Ref.30089693]TZM-bl cell:CC50=112.9 ± 2.21 µM ##MT-4 cell:CC50=94.06± 4.97 µM ##HEK293T cell:CC50=88.86± 6.68µM ##PBMC:CC50=114.8± 12.68 µM.

Source & Reference

NA
DRAMP
J Virol. 2018 Sep 26 92(20):e01088-18.